Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years

Eye

Volumn 21, Issue 3, 2007, Pages 321-323

  Islam, M S ^a   Vernon, S A ^a   Negi, A ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CASE STUDY; CATARACT; CATARACT EXTRACTION; CATARACTOGENESIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; FISHER EXACT TEST; FOLLOW UP; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SUBCAPSULAR CATARACT;

EID: 33847637137     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702304     Document Type: Article

References (15)

1. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002; 109: 920-927.
2. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular oedema. Ophthalmology 2004; 111: 218-225.
3. Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Ophthalmology 2004; 111: 2044-2049.
4. Karacorlu M, Ozdemir H, Karacorlu S, Alacali N, Mudun B, Burumcek E. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye, advance online publication 13. 8. 04 sj.eye.6701512.
5. Ozkkiris A, Evereklioglu C, Erkilic K, Tamcelik N, Mirza E. Intravitreal triamcinolone acetonide injection as a primary treatment for diabetic macular oedema. Eur J Ophthalmol 2004; 14(6): 543-549.
6. Negi AK, Vernon SA, Lim CS, Owen-Armstrong K. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye 2004 (E-pub ahead of print).
7. Islam MS, Negi A, Vernon SA. Improved visual acuity and macular thickness 1 week after intravitreal triamcinolone for diabetic macular oedema. Eye 2004 (E-pub ahead of print).
8. Kanski JJ. Clinical Ophthalmology A Systematic Approach, 5th Ed. p 167.
9. Gupta R, Negi AK, Vernon SA. Severe sub-conjunctival haemorrhage following Intravitreal triamcinolone for refractory diabetic oedema. Eye 2005; 19: 590-591.
10. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular oedema. Arch Ophthalmol 2003; 121: 57-61.
11. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: An ocular coherence tomography study. Br J Ophthalmol 2004; 88: 1131-1136.
12. Lam DSC, Chan CKM, Tang EWH, Li KKW, Fan DSP, Chan WM. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: Six month prospective longitudinal pilot study. Clin Exp Ophthalmol 2004; 32: 569-572.
13. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al. Safety of an intravitreal injection of triamcinolone. Arch Ophthalmol 2004; 122: 336-340.
14. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005; 112: 139-143.
15. Flynn HW, Scott IU. Intravitreal triamcinolone acetonide for macular oedema associated with diabetic retinopathy and venous occlusive disease: It's time for clinical trials. Arch Ophthalmol 2005; 123: 258-259.